Repligen reported $63.17M in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Agilent A:US $ 411M 51M
Align Technology ALGN:US $ 188.2M 9.89M
Biomarin Pharmaceutical BMRN:US $ 39.15M 98.18M
Bristol Myers Squibb BMY:US $ 2590M 37M
Bruker BRKR:US $ 73.9M 22.6M
Catalent CTLT:US $ 246M 35M
Charles River Laboratories CRL:US $ 187.41M 38.63M
Danaher DHR:US $ 2205M 33M
Exact Sciences EXAS:US $ -159.58M 17.4M
General Electric GE:US $ 851M 1567M
Henry Schein HSIC:US $ 220M 24M
Illumina ILMN:US $ -579000000 763M
IQVIA Holdings Inc IQV:US $ 453M 42M
Mettler Toledo International MTD:US 256.69M 43.69M
Myriad Genetics MYGN:US $ -17.8M 7.8M
Nanostring Technologies NSTG:US $ -37.09M 0.38M
Pacific Biosciences Of California PACB:US $ -67.97M 9.55M
Patterson Companies PDCO:US $ 34.84M 37.99M
Peregrine Pharmaceuticals PPHM:US $ 2.74M 1.67M
Perkinelmer PKI:US $ 250.86M 3.99M
Pfizer PFE:US $ 12102M 2229M
Repligen RGEN:US $ 63.17M 3.17M
Thermo Fisher Scientific TMO:US $ 2001M 820M
Waters WAT:US $ 199.63M 4.16M
West Pharmaceutical Services WST:US $ 228M 38.8M